Home / Stocks / Indegene Limited
INDGN

Indegene Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹645.4

Change

-9.55 (-1.46%)

Open

₹656.0

Prev. Close

₹654.95

Day High

₹661.0

Day Low

₹642.0

Volume Analysis

Traded

396,327

Delivered

212,398

Delivery %

53.59%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year revenue growth (15.0%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹675.94 ₹668.47 ₹656.94 ₹649.47 ₹637.94 ₹630.47 ₹618.94
Fibonacci ₹668.47 ₹661.21 ₹656.73 ₹649.47 ₹642.21 ₹637.73 ₹630.47
Camarilla ₹650.63 ₹648.88 ₹647.14 ₹649.47 ₹643.66 ₹641.92 ₹640.18

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+24.1%

1 Week

-3.1%

1 Month

+9.71%

3 Months

+13.67%

6 Months

+26.91%

1 Year

+25.39%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹228.19

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

10.45%

Net margin 9.95% × asset turnover 0.75x × equity multiplier 1.4x

Company Overview

Sector

Healthcare

Market Cap

₹15,640 Cr

P/E (TTM)

36.7

ROE

14.4%

Book Value

₹139.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Indegene Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 73/100. The strongest factor is Financial Strength (100/100), while Valuation (32/100) is the weakest area to weigh before deciding. Strong 3-year revenue growth (15.0%).

TopFund Score — Fundamentals Quality

73/100 — Good

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

83

Valuation

32

Cash Flow

69

Corporate Governance

65

Momentum

89

Institutional Ownership

71

Business Quality

70

Risk & Volatility

74

Liquidity

79

From Screener.in

  • +Company is almost debt free.
  • +Company is expected to give good quarter

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Indegene schedules 1x1 investor meeting with Mirabilis Investment Trust on 13 November 2026 in Bengaluru.

Indegene released audio recording of Q2 and H1 FY27 earnings call held on 30 October 2026.

Audio recording of Q2 and half-year FY27 earnings call held on 30 October 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 636 673 673 676 687 720 756 761 804 942 1,003 1,063 1,122
Expenses + 515 524 534 548 561 589 608 606 664 783 840 889 937
Operating Profit 121 149 139 129 126 132 148 155 141 160 164 174 186
OPM % 19.0% 22.0% 21.0% 19.0% 18.0% 18.0% 20.0% 20.0% 17.0% 17.0% 16.0% 16.0% 17.0%
Other Income + 12 13 26 22 21 38 26 22 20 19 -10 29 15
Interest 12 12 12 12 4 3 3 4 4 5 7 6 7
Depreciation 20 18 18 20 19 20 21 22 23 40 42 44 46
Profit before tax 101 132 134 120 124 146 149 152 133 135 105 153 147
Tax % 25.0% 25.0% 29.0% 27.0% 26.0% 25.0% 21.0% 23.0% 23.0% 24.0% 24.0% 24.0% 24.0%
Net Profit + 75 99 95 88 92 110 118 116 102 103 80 116 112
EPS in Rs 3 4 4 4 4 5 5 5 4 4 3 5 5
Raw PDF — — — — — — — — — — — — —
YoY Sales growth — — 6 11 8 7 12 12 17 31 33 40 40

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 553 643 966 1,665 2,306 2,590 2,839 3,510 4,131
Expenses + 511 499 736 1,378 1,910 2,084 2,292 2,892 3,448
Operating Profit 42 144 230 287 396 505 548 619 683
OPM % 8.0% 22.0% 24.0% 17.0% 17.0% 20.0% 19.0% 18.0% 17.0%
Other Income + 7 -102 -3 -21 58 79 94 52 54
Interest 6 9 7 6 31 49 22 19 25
Depreciation 17 19 26 33 60 76 80 126 172
Profit before tax 26 14 195 226 363 459 539 525 540
Tax % 45.0% 191.0% 23.0% 28.0% 27.0% 27.0% 25.0% 24.0% —
Net Profit + 14 -12 149 163 266 337 407 401 411
EPS in Rs 1 0 7 7 12 15 17 17 17
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 12.0% 13.0% —
Sales growth — 16 50 72 39 12 10 24 36

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 73 -105 324 764 1,020 1,385 2,568 3,091 3,310
Borrowings + 147 483 51 66 502 490 102 144 157
Other Liabilities + 108 222 220 524 638 627 609 1,337 1,178
Total Liabilities 329 600 596 1,353 2,204 2,546 3,326 4,620 4,693
Fixed Assets + 104 119 86 138 664 646 678 1,812 1,830
CWIP 0 0 0 0 0 0 4 12 0
Investments 0 13 0 120 614 796 1,290 1,100 1,019
Other Assets + 225 468 510 1,096 926 1,103 1,355 1,697 1,844
Total Assets 329 600 596 1,353 2,204 2,546 3,326 4,620 4,693
Equity Capital 0 0 0 0 44 44 48 48 48

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 65 22 172 297 130 508 442 651
Cash from Investing Activity + -18 -16 -81 -158 -896 -326 -677 -508
Cash from Financing Activity + -21 136 -132 233 333 -66 288 -83
Net Cash Flow 25 143 -40 373 -433 115 52 60
Free Cash Flow 48 16 151 272 111 497 412 606
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 196 34 96 128 60 125 110 129

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

  Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 92.38% 92.01% 91.01% 89.8% 82.75% 81.74% 80.44% 81.43% 81.34% 71.76%
FII 3.79% 4.82% 5.03% 5.24% 10.04% 11.3% 11.48% 10.27% 9.92% 12.4%
DII 3.84% 3.17% 3.99% 4.96% 7.2% 6.95% 8.06% 8.29% 8.74% 15.82%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Indegene Limited (this stock) 15,640 36.7 4.67 14.4%
Natco Pharma Ltd. 15,881 19.1 1.5 17.1%
Jubilant Pharmova Ltd 14,883 50.4 2.08 6.53%
Vijaya Diagnostic Cen Ltd 14,524 71.3 13.69 18.9%
Poly Medicure Limited 17,041 53.9 5.22 9.8%
Molbio Diagnostics Ltd 17,111 236.0 11.89 15.6%
Corona Remedies Limited 14,010 63.6 17.34 29.5%

Which Mutual Funds Hold Indegene Limited?

Frequently Asked Questions about Indegene Limited

Community Sentiment

What are other investors saying about Indegene Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.